Karamanlıoğlu, Beyhan2024-07-122024-07-122003Karamanlıoğlu, B. ve Aktaş, R. G. (2003). Do deferoxamine, ticlopidin or trimetazidine prevent sevoflurane nephrotoxicity? An electron microscopic study. Microscopy and Microanalysis, Cambridge University Press. 9, s. 1428-1429.1435-8115https://www.cambridge.org/core/journals/microscopy-and-microanalysis/article/do-deferoxamine-ticlopidin-or-trimetazidine-prevent-sevoflurane-nephrotoxicity-an-electron-microscopic-study/226E6AEA4E9FD98B471ABE350D92C5D4https://hdl.handle.net/20.500.12415/4215Sevoflurane is a common anesthetic drug. Several biochemical, pharmacologic and physiologic studies have showed nephrotoxicity of Sevoflurane[1,2,3]. Histopathologic studies reported tubular damage and tubular cellular hyperplasia after the administration of Sevoflurane[4]. Deferoxamine(DFO) is known to protect against myoglobinuric acute renal failure[5]. It has been suggested that Ticlopidine(TIC) does not prevent nephropathies but has beneficial effects[6]. Fang et al. showed that TIC inhibited mesangial cell proliferation and collagen synthesis[7]. There is another study reporting that TIC induces acute interstitial nephrite and cause an increase of the number of lymphocytes and eosinophil leucocytes in interstitial tissue[8]. Trimetazidine(TMZ) has anti-ischemic effects and protects tissue damage in kidney[5, 9, 10, 11]. These studies lead us to investigate if DFO, TIC or TMZ can prevent the nephrotoxicity of Sevoflurane at morphologic level.enCC0 1.0 Universalinfo:eu-repo/semantics/openAccessArticle1429Q314289